Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Fulcrum Therapeutics, Inc. lost approximately half its market value after disclosing FDA safety concerns leading the company to discontinue its lead sickle-cell candidate.*
SEC filings reflected insider equity holdings and awards totaling more than 264,000 shares
Fulcrum Therapeutics, Inc. guided investors toward a Phase III future for pociredir while a $25.1 million facility lease locked the company into infrastructure now stranded by program termination.
― Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik ® (tazemetostat) and the product’s subsequent global withdrawal on the benefit-risk...
CAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...
― Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive...
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Fulcrum) (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improve...
Barchart Research What to Expect from FULC Earnings FULC Generated April 24, 2026 Current Price $7.84 EPS Estimate $$-0.31 Consensus Rating Moderate Buy Average Move 9.72% Can Fulcrum Therapeutics Translate...